RCS - Ondine Biomedical - Steriwave in first Australian hospital

Ondine BiomedicalAnnouncement

22/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240422:nRSV4145La&default-theme=true

RNS Number : 4145L  Ondine Biomedical Inc.  22 April 2024

Non-regulatory announcement

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Steriwave in first Australian hospital

Mater Hospital, North Sydney has become the first Australian hospital to use
Ondine Biomedical's award-winning light-activated antimicrobial technology

Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company
pioneering light-activated antimicrobial treatments, announces that Mater
Hospital, North Sydney, a private hospital in New South Wales, has become the
first Australian hospital to start using its light-activated antimicrobial
Steriwave® technology to prevent the spread of hospital-acquired infections
(HAIs). Mater Hospital, located in North Sydney and founded in 1906, is part
of St. Vincent's Health Australia Group, Australia's largest not-for-profit
provider of health and aged care services.

Medical Oncologist, Professor Frances Boyle AM, Director of the Patricia
Ritchie Centre for Cancer Care and Research at Mater Hospital and Professor of
Medical Oncology at the University of Sydney, said: "We are very pleased to be
the first hospital in Australia to have the Steriwave nasal decolonization
system. The pathogens patients carry have long been known to cause
hospital-acquired infections, especially for the weak and immunocompromised.
Having a rapid non-antibiotic approach to decolonizing the nose - a major
source of infection transmission - is a benefit to our patients."

Orthopaedic Spine Surgeon Dr John Street, Director of the Integrated
Ambulatory Spine Program at Vancouver Coastal Health and upcoming President of
the Canadian Spine Society, was a keynote speaker at the recent 2024 Spine
Society of Australia 35th Annual Scientific Meeting
(https://www.dcconferences.com.au/ssa2024/Keynote_Speakers) that was held in
Sydney on April 5-7(th), 2024. Dr Street presented the results of his team's
14-year study evaluating Steriwave's effect on SSIs
(https://www.canjsurg.ca/content/66/6/E550) following spine surgery at
Vancouver General Hospital ("VGH"), concluding that Steriwave nasal
photodisinfection should be part of routine use and recommended it as standard
of care for all elective and emergent spine surgeries.

The VGH research involved 13,493 patients and demonstrated a 66.5% reduction
(7.98% vs 2.67%, p<0.001) in surgical site infections (SSIs) following
spine surgery when Ondine's Steriwave nasal photodisinfection (nPDT) was
implemented in the universal pre-surgical infection prevention protocol. The
researchers also found average net annual cost saving of $2.49 million, a
saving of over $2,400 per spine surgery patient, post rollout.

**ENDS**

Enquiries:

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                        +001 (604) 665 0555

 Singer Capital Markets

(Nominated Adviser and Joint Broker)
 Aubrey Powell, Sam Butcher                +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan            +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard          +44 (0)77 1000 5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader
innovating light-activated antimicrobial therapies (also known as
'photodisinfection'). Ondine has a pipeline of investigational products, based
on its proprietary photodisinfection technology, in various stages of
development.

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and
is approved in Canada and several other countries under the name Steriwave®.
In the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently undergoing
clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns, and many other
indications.

About Steriwave®

Ondine's Steriwave® nasal photodisinfection system is a patented technology
using a proprietary light-activated antimicrobial (photosensitizer) to destroy
bacteria, viruses, and fungi colonizing the nose. The photodisinfection
treatment is carried out by a trained healthcare professional and is an easy
to use, painless, two-step process. The photosensitizer is applied to each
nostril using a nasal swab, followed by illumination of the area with a
specific wavelength of red laser light for less than five minutes. The light
activates the photosensitizer, causing an oxidative burst that is lethal to
all types of pathogens without causing long-term adverse effects on the nasal
microbiome. A key benefit of this approach-unlike with antibiotics, which have
resistance rates reported as high as 81%( 1 )-is that pathogens do not develop
resistance to the therapy.

Nasal decolonization is recommended in the 2016 WHO Global guidelines for the
prevention of surgical site infections,( 2 ) and the Society for Healthcare
Epidemiology of America (SHEA) guidelines, published in May 2023, recommend
nasal decolonization for major surgical procedures.( 3 )

 

 1  Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical
implications and potential alternatives for the eradication of MRSA. J
Antimicrob Chemother. 2015;70(10):2681-2692. doi:10.1093/jac/dkv169

 2 
https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2

 3  Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent
surgical site infections in acute-care hospitals: 2022 Update. Infect Control
Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEFLFLZZLBBBB